XML 86 R74.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue recognition - Collaboration and Royalty Revenue (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jan. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
product
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Nov. 30, 2011
USD ($)
Revenue recognition                  
Number of approved products | product           2      
Remaining potential milestones that can be achieved               $ 150,000  
Revenue   $ 211,007 $ 196,786     $ 1,565,978 $ 593,608    
Deferred revenue   1,691       1,691   $ 5,505  
Collaboration and license revenue                  
Revenue recognition                  
Revenue   9,258       998,430      
Royalty revenue                  
Revenue recognition                  
Revenue   70,793 61,365     $ 164,837 145,702    
SMA License Agreement                  
Revenue recognition                  
Number of approved products | product           1      
SMA License Agreement | Collaboration and license revenue                  
Revenue recognition                  
Revenue       $ 0 $ 0        
SMA License Agreement | Royalty revenue                  
Revenue recognition                  
Revenue   70,800 $ 61,400     $ 164,800 $ 145,700    
License and Collaboration Agreement                  
Revenue recognition                  
Refund of revenue related to prior collaboration arrangements           3,500      
License and Collaboration Agreement | Novartis                  
Revenue recognition                  
Cash proceeds from upfront payment on collaboration agreement $ 1,000,000                
Percentage share of the income (loss) generated on U.S. sales 40.00%                
Deferred revenue   0       0      
License and Collaboration Agreement | Novartis | Collaboration and license revenue                  
Revenue recognition                  
Revenue   9,300       1,000,000      
Research And Development Event Milestones | SMA License Agreement                  
Revenue recognition                  
Remaining potential milestones that can be achieved   0       0      
Sales Milestones | SMA License Agreement                  
Revenue recognition                  
Remaining potential milestones that can be achieved   $ 150,000       $ 150,000      
Maximum | License and Collaboration Agreement | Novartis                  
Revenue recognition                  
Potential future proceeds contingent on achievement of developmental, regulatory and sales milestones and tiered royalties $ 1,900,000                
Maximum | Research And Development Event Milestones | SMA License Agreement                  
Revenue recognition                  
Remaining potential milestones that can be achieved                 $ 135,000
Maximum | Sales Milestones | SMA License Agreement                  
Revenue recognition                  
Remaining potential milestones that can be achieved                 $ 325,000